In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Repetitive levosimendan infusions for patients with advanced chronic heart failure in the vulnerable post-discharge period: the LeoDOR Trial

Session Rapid Fire 4 - Chronic heart failure - Pharmacology

Speaker Associate Professor Gerhard Polzl

Congress : Heart Failure 2019

  • Topic : heart failure
  • Sub-topic : Heart Failure with Reduced Ejection Fraction
  • Session type : Rapid Fire Abstracts
  • FP Number : 1290

Authors : G Polzl (Innsbruck,AT), J Comin-Colet (Barcelona,ES), JF Delgado (Madrid,ES), F Fedele (Rome,IT), MJ Garcia-Gonzales (San Cristobal,ES), F Gustafsson (Copenhagen,DK), JF Masip (Barcelona,ES), Z Papp (Debrecen,HU), S Stoerk (Wuerzburg,DE), H Ulmer (Innsbruck,AT), B Vrtovec (Ljubljana,SI), G Wikstroem (Uppsala,SE), JF Altenberger (Grossgmain,AT)

Authors:
G Polzl1 , J Comin-Colet2 , JF Delgado3 , F Fedele4 , MJ Garcia-Gonzales5 , F Gustafsson6 , JF Masip7 , Z Papp8 , S Stoerk9 , H Ulmer10 , B Vrtovec11 , G Wikstroem12 , JF Altenberger13 , 1Department of Internal Medicine III - Cardiology - Innsbruck - Austria , 2University Hospital of Bellvitge, Cardiology - Barcelona - Spain , 3University Hospital 12 de Octubre, Cardiology - Madrid - Spain , 4Sapienza University of Rome, Cardiovascular Science - Rome - Italy , 5University Hospital Canarias, Cardiology - San Cristobal - Spain , 6University of Copenhagen, Cardiology - Copenhagen - Denmark , 7University of Barcelona, Intensive Care - Barcelona - Spain , 8University of Debrecen, Cardiology - Debrecen - Hungary , 9University Hospital Würzburg - Wuerzburg - Germany , 10Innsbruck Medical University - Innsbruck - Austria , 11University Medical Centre of Ljubljana, Cardiology - Ljubljana - Slovenia , 12Uppsala University Hospital - Uppsala - Sweden , 13Centre for Cardiac Rehabilitation Grossgmain - Grossgmain - Austria ,

Citation:

Background

Readmission and mortality rates are high during the vulnerable period following an episode of acute heart failure. Experience in several clinical studies has indicated that administration of intravenous levosimendan in intermittent cycles may be effective in patients with advanced HF. We here describe the rationale and protocol of the LeoDOR study that will assess the efficacy and safety of intermittent levosimendan therapy during the vulnerable phase after a recent hospitalisation for acute HF in advanced HFrEF patients. The overarching hypothesis is that, compared with placebo, repetitive administration of levosimendan during the post-acute phase will be associated with greater clinical stability over a follow-up period of 14 weeks.

Methods

The LeoDOR study is a randomised, double-blind, placebo-controlled, three-armed trial designed to evaluate the efficacy and safety of intermittent levosimendan therapy, administered in addition to standard therapy for a period of 12 weeks either as a 6-h continuous infusion at a rate of 0.2 µg/kg/min every 2 weeks or as a 24-h continuous infusion at a rate of 0.1 µg/kg/min every 3 weeks. The primary endpoint will be evaluated after 14 weeks. Information on safety events will be obtained after 6 months. The study that was started in March 2018 intends to include 264 patients in 30 centres in nine European countries.

The primary efficacy assessment will be made using a global rank endpoint in which all participants are ranked across three hierarchical groups: (i) time to death or urgent heart transplantation or implantation of a ventricular assist device (VAD); (ii) time to non-fatal HF requiring i.v. vasoactive therapy; and (iii) time-averaged proportional change in N-terminal pro-brain natriuretic peptide (NT-proBNP) from baseline to week 14 with (i) as the most important event. Secondary efficacy endpoints include individual components of the primary endpoint at short- (14 weeks) and intermediate-term (26 weeks) follow-up, as well as changes in functional status.

Conclusion

The LeoDOR trial will test efficacy and safety of intermittent levosimendan therapy in patients with "very" advanced but not acute heart failure with the highest short- and long-term mortality and rehospitalisation rates. The study is configured to examine evidence of efficacy of an intensified therapy using clinically relevant endpoints for severely ill patients managed on an outpatient basis.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members



Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are